ERYTECH fornisce un aggiornamento sullo studio di fase 2 sponsorizzato dallo sperimentatore di Eryaspase per il trattamento di seconda linea della leucemia linfoblastica acuta

NEXT STORY
Opthea Reports Positive Phase 2a Trial Results of OPT-302 in Diabetic Macular Edema
PREV STORY
ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Initial Data from Shire Collaboration Identifies Key Biomarkers That Affect Bleeding Patterns, Response to Treatment for Hemophilia A

Initial Data from Shire Collaboration Identifies Key Biomarkers That Affect Bleeding Patterns, Response to ...

author_avatar
NASDAQ Market News

Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results

ATLANTA, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its ...

author_avatar
NASDAQ Market News

Curis Announces Appointment of Lori A. Kunkel, M.D. to Board of Directors

LEXINGTON, Mass., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company ...

author_avatar
NASDAQ Market News